Update on the treatment of small cell lung cancer (SCLC)

被引：6

作者：

Ardizzoni, A ^{[1
]}

Grossi, F

机构：

[1] Ist Nazl Ric Canc, I-16132 Genoa, Italy

[2] Univ Udine, Clin Oncol, Udine, Italy

来源：

ANNALS OF ONCOLOGY | 2000年 / 11卷

关键词：

D O I：

10.1023/A:1011115713452

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：101 / 108

页数：8

共 82 条

[1] Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease [J].

Ardizzoni, A ;

Hansen, H ;

Dombernowsky, P ;

Gamucci, T ;

Kaplan, S ;

Postmus, P ;

Giaccone, G ;

Schaefer, B ;

Wanders, J ;

Verweij, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2090-2096

[2] INITIAL CHEMOTHERAPEUTIC DOSES AND SURVIVAL IN PATIENTS WITH LIMITED SMALL-CELL LUNG-CANCER [J].

ARRIAGADA, R ;

LECHEVALIER, T ;

PIGNON, JP ;

RIVIERE, A ;

MONNET, I ;

CHOMY, P ;

TUCHAIS, C ;

TARAYRE, M ;

RUFFIE, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (25) :1848-1852

[3] Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission [J].

Aupérin, A ;

Arriagada, R ;

Pignon, JP ;

Le Péchoux, C ;

Gregor, A ;

Stephens, RJ ;

Kristjansen, PEG ;

Johnson, BE ;

Ueoka, H ;

Wagner, H ;

Aisner, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :476-484

[4] Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung [J].

Beith, JM ;

Clarke, SJ ;

Woods, RL ;

Bell, DR ;

Levi, JA .

EUROPEAN JOURNAL OF CANCER, 1996, 32A (03) :438-443

[5]

BLEEHEN NM, 1989, BRIT J CANCER, V59, P584

[6] A RANDOMIZED TRIAL OF 3 OR 6 COURSES OF ETOPOSIDE CYCLOPHOSPHAMIDE METHOTREXATE AND VINCRISTINE OR 6 COURSES OF ETOPOSIDE AND IFOSFAMIDE IN SMALL-CELL LUNG-CANCER (SCLC) .1. SURVIVAL AND PROGNOSTIC FACTORS [J].

BLEEHEN, NM ;

GIRLING, DJ ;

MACHIN, D ;

STEPHENS, RJ ;

BARLEY, VL ;

BULLIMORE, JA ;

WHITE, RJ ;

BLEEHAN, NM ;

WILLIAMS, MV ;

BREDIN, CP ;

DAVIDSON, AR ;

WILLIAMS, TJ ;

ASH, DV ;

CLOSE, HJ ;

JOSLIN, CA ;

MUERS, MF ;

STONE, J ;

ASHFORD, RF ;

DISCHE, S ;

DUNPHY, EP ;

FERMONT, DC ;

GROSCH, E ;

MAHER, EJ ;

SAUNDERS, MI ;

ADAM, RJ ;

ALCOCK, CJ ;

BENSON, MK ;

HOPKIN, JM ;

LANE, DJ ;

HUNTER, AM .

BRITISH JOURNAL OF CANCER, 1993, 68 (06) :1150-1156

[7] Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma [J].

Bonner, JA ;

Sloan, JA ;

Shanahan, TG ;

Brooks, BJ ;

Marks, RS ;

Krook, JE ;

Gerstner, JB ;

Maksymiuk, A ;

Levitt, R ;

Mailliard, JA ;

Tazelaar, HD ;

Hillman, S ;

Jett, JR .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2681-2691

[8]

BURRIS HA, 1998, P AN M AM SOC CLIN, V17, pA451

[9] MAINTENANCE CHEMOTHERAPY IN LIMITED SMALL CELL LUNG-CANCER - A RANDOMIZED CONTROLLED CLINICAL-TRIAL [J].

BYRNE, MJ ;

VANHAZEL, G ;

TROTTER, J ;

CAMERON, F ;

SHEPHERD, J ;

CASSIDY, B ;

GEBSKI, V .

BRITISH JOURNAL OF CANCER, 1989, 60 (03) :413-418

[10] Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer [J].

Choi, NC ;

Herndon, JE ;

Rosenman, J ;

Carey, RW ;

Chung, CT ;

Bernard, S ;

Leone, L ;

Seagren, S ;

Green, M .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3528-3536

← 1 2 3 4 5 6 7 8 9 →